Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash from Investing Activities: 2010-2025

Historic Cash from Investing Activities for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to -$6.2 million.

  • Ani Pharmaceuticals' Cash from Investing Activities rose 98.45% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.6 million, marking a year-over-year increase of 89.07%. This contributed to the annual value of -$404.7 million for FY2024, which is 2086.37% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Cash from Investing Activities is -$6.2 million, which was up 10.80% from -$6.9 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $8.9 million during Q1 2024, with a 5-year trough of -$398.5 million in Q3 2024.
  • For the 3-year period, Ani Pharmaceuticals' Cash from Investing Activities averaged around -$41.5 million, with its median value being -$6.2 million (2025).
  • Over the last 5 years, Ani Pharmaceuticals' Cash from Investing Activities had its largest YoY gain of 479.64% in 2024, and its largest YoY loss of 8,652.95% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$82.2 million in 2021, then surged by 96.18% to -$3.1 million in 2022, then plummeted by 52.10% to -$4.8 million in 2023, then slumped by 123.50% to -$10.7 million in 2024, then spiked by 98.45% to -$6.2 million in 2025.
  • Its Cash from Investing Activities stands at -$6.2 million for Q3 2025, versus -$6.9 million for Q2 2025 and -$19.8 million for Q1 2025.